Gestational Diabetes
A Step 2 CK–focused walkthrough of gestational diabetes: hPL-driven insulin resistance, the two-step vs one-step screening/diagnosis pathway, diet-then-insulin management with glucose targets, and delivery/postpartum decisions — anchored by the classic board discriminator that GDM (unlike pregestational DM) causes no congenital anomalies. Every cutoff and next-best-step verified against ACOG standards.
The concept in one arc
Gestational diabetes mellitus (GDM) is glucose intolerance first recognized during pregnancy. Placental hormones — chiefly human placental lactogen (hPL), plus progesterone, cortisol, and prolactin — drive insulin resistance that rises across the 2nd trimester and peaks in the 3rd, which is exactly why screening is timed to 24–28 weeks. A patient whose β-cells cannot out-secrete this resistance becomes hyperglycemic.
The single highest-yield discriminator: because GDM emerges after the first trimester (after organogenesis), it does not cause congenital malformations — unlike pregestational diabetes. Instead the fetus faces problems of excess growth and hyperinsulinemia: macrosomia, birth trauma, and neonatal hypoglycemia.
Expect a predictable chain of decisions: universal screening at 24–28 weeks → confirmatory OGTT → diet first, insulin if uncontrolled → fetal surveillance and delivery timing → postpartum reclassification.
- Universal screen at 24–28 weeks: non-fasting 50 g 1-hour glucose challenge test (GCT)
- Early screen at the first prenatal visit if high risk: obesity (BMI ≥30), prior GDM, prior macrosomic infant, strong family history, PCOS, glucosuria
- GCT ≥140 mg/dL (some centers use 130–135 for higher sensitivity) → proceed to the diagnostic OGTT; a 1-h ≥200 is often treated as GDM outright
- Two-step (Carpenter-Coustan) — US standard: fasting 100 g 3-hour OGTT; need ≥2 abnormal values → FPG ≥95, 1h ≥180, 2h ≥155, 3h ≥140
- One-step (IADPSG): fasting 75 g 2-hour OGTT; only ≥1 abnormal → FPG ≥92, 1h ≥180, 2h ≥153
- Classify: A1GDM = diet-controlled; A2GDM = requires medication
Two-step vs one-step diagnosis
| Feature | Two-step (US standard) | One-step (IADPSG) |
|---|---|---|
| Screening step | 50 g 1-h GCT (≥140) first | None — go straight to OGTT |
| Diagnostic test | 100 g 3-h OGTT (fasting) | 75 g 2-h OGTT (fasting) |
| Abnormal values needed | ≥2 | ≥1 |
| Cutoffs, mg/dL (F/1h/2h/3h) | 95 / 180 / 155 / 140 | 92 / 180 / 153 |
| Net effect | Fewer diagnoses | More diagnoses |
Stem: A 29-year-old at 26 weeks has a routine non-fasting 50 g GCT of 168 mg/dL. She feels well.
Next best step: This is a screen, not a diagnosis → order the 100 g 3-hour OGTT (do not start treatment yet).
Follow-up: Fasting 98, 1h 190, 2h 150, 3h 120 → two abnormal values (fasting ≥95 + 1-h ≥180) meet Carpenter-Coustan → GDM confirmed.
Management now: Begin nutritional therapy + moderate exercise and self-monitored blood glucose (fasting and 1–2 h postprandial). Do not start a drug reflexively — most patients meet targets on diet alone (A1GDM).
Case 1: After 1–2 weeks of diet, her log shows fasting values 105–115 and 1-h postprandial in the 150s — above the targets of <95 and <140. Next step: Add pharmacotherapy — insulin is first-line (does not cross the placenta); metformin/glyburide are alternatives that do cross. She is now A2GDM → begin antenatal fetal surveillance and monitor growth.
Case 2: A term infant of a mother with GDM becomes jittery and tremulous ~1 hour after birth. Dx / next step: Neonatal hypoglycemia from fetal hyperinsulinemia → check a glucose, feed early, and give IV dextrose if severe or symptomatic.
- First-line: medical nutrition therapy + exercise + glucose self-monitoring
- Glucose targets: fasting <95, 1-h postprandial <140, 2-h postprandial <120 mg/dL
- Uncontrolled → insulin (preferred/first-line); metformin and glyburide cross the placenta and are alternatives
- A2GDM / poorly controlled: antenatal testing (NST, AFI) plus growth ultrasounds
- Delivery timing: well-controlled A1GDM at 39–40+6 wks; well-controlled A2GDM ~39–39+6 wks; poorly controlled → individualize earlier (37–38+6)
- Macrosomia: offer cesarean if estimated fetal weight ≥4500 g in diabetics (shoulder-dystocia risk)
- Postpartum: 75 g 2-hour OGTT at 4–12 weeks to reclassify; ~50% develop type 2 diabetes over the following 10–20 years
Diagnostic cutoffs — the ladder peaks then falls:
- Two-step 3-h (100 g): 95 → 180 → 155 → 140. Fasting climbs to a 1-h peak, then declines. Need 2 to diagnose.
- One-step 2-h (75 g): 92 → 180 → 153. Need just 1.
- Treatment targets are lower/rounder: 95 / 140 / 120 (fasting / 1-h / 2-h postprandial).
Board discriminator (a true classic): GDM = NO congenital anomalies (arises after organogenesis). If the stem shows caudal regression syndrome, transposition of the great vessels, or NTDs → think pregestational diabetes, not GDM.
Pregestational vs gestational diabetes
| Feature | Pregestational DM | Gestational DM |
|---|---|---|
| Hyperglycemia timing | Present at conception/organogenesis | Onset after 1st trimester |
| Congenital anomalies | Yes — caudal regression (classic), cardiac (TGA, VSD), NTDs | No |
| Spontaneous abortion | Increased | Baseline |
| Shared neonatal risks | Macrosomia, hypoglycemia, RDS, polycythemia, hypocalcemia | Same — macrosomia, hypoglycemia, RDS, polycythemia, hypocalcemia |
| Key workup point | Preconception HbA1c optimization | Screen at 24–28 wks; postpartum OGTT |
Practice OB/GYN now
Board-style questions, spaced-repetition flashcards, and a Socratic AI tutor — free to start.